The pharmacological treatment of acute HIV infections in neonates

References

• Siegfried N, Van Der Merwe L, Brocklehurst P, et al. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Sys Rev. 2011;7:CD003510.
   PubMed Web of Science ®Google Scholar
• UNAIDS. AIDSinfo Online Database. 2017. [cited 2017 Oct 30]. Available from: http://aidsinfo.unaids.org/]
   Google Scholar
• De Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. Jama. 2000;284(2):190–197.
   PubMed Web of Science ®Google Scholar
• Chiappini E, Galli L, Tovo PA, et al. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS (London, England). 2006;20(2):207–215.
   PubMed Web of Science ®Google Scholar
• Chun TW, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol. 2015;16(6):584–589.
   PubMed Web of Science ®Google Scholar
• Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233–2244.
   PubMed Web of Science ®Google Scholar
• Organization WH. 2010. Antiretroviral therapy for HIV infection in infants and children: towards universal access - recommendations for a public health approach: 2010 revision. [cited 2017 Oct 30]. Available from: http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html.
   Google Scholar
• World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: World Health Organization; 2016.
   Google Scholar
• Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–822.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
   PubMed Web of Science ®Google Scholar
• Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. Jama. 1998;279(10):756–761.
   PubMed Web of Science ®Google Scholar
• Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med. 1997;336(19):1337–1342.
   PubMed Web of Science ®Google Scholar
• De Rossi A, Masiero S, Giaquinto C, et al. Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J Clin Invest. 1996;97(2):323–330.
   PubMed Web of Science ®Google Scholar
• Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364(9441):1236–1243.
   PubMed Web of Science ®Google Scholar
• Sutcliffe CG, Scott S, Mugala N, et al. Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy. Clinical Infect Dis: Official Pub Infect Dis Soc Am. 2008;47(6):837–844.
   PubMed Web of Science ®Google Scholar
• Tobin NH, Aldrovandi GM. Immunology of pediatric HIV infection. Immunol Rev. 2013;254(1):143–169.
   PubMed Web of Science ®Google Scholar
• Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003;112(5):973–980.
   PubMed Web of Science ®Google Scholar
• Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–954.
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119–129.
   PubMed Web of Science ®Google Scholar
• Dankner WM, Lindsey JC, Levin MJ. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J. 2001;20(1):40–48.
   PubMed Web of Science ®Google Scholar
• Mphatswe W, Blanckenberg N, Tudor-Williams G, et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS (London, England). 2007;21(10):1253–1261.
   PubMed Web of Science ®Google Scholar
• Innes S, Lazarus E, Otwombe K, et al. Early severe HIV disease precedes early antiretroviral therapy in infants: are we too late? J Int AIDS Soc. 2014;17:18914.
   PubMed Web of Science ®Google Scholar
• Abrams EJ, Woldesenbet S, Soares Silva J, et al. Despite access to antiretrovirals for prevention and treatment, high rates of mortality persist among hiv-infected infants and young children. Pediatr Infect Dis J. 2017;36(6):595–601.
   PubMed Web of Science ®Google Scholar
• Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369(19):1828–1835.
   PubMed Web of Science ®Google Scholar
• Luzuriaga K, Gay H, Ziemniak C, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med. 2015;372(8):786–788.
   PubMed Web of Science ®Google Scholar
• Ananworanich J, Chomont N, Eller LA, et al. HIV DNA set point is rapidly established in acute hiv infection and dramatically reduced by early ART. EBioMedicine. 2016;11:68–72.
   PubMed Web of Science ®Google Scholar
• Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis. 2013;208(8):1202–1211.
   PubMed Web of Science ®Google Scholar
• Laanani M, Ghosn J, Essat A, et al. Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA. Clinical Infect Dis: Official Pub Infect Dis Soc Am. 2015;60(11):1715–1721.
   PubMed Web of Science ®Google Scholar
• Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9(3):e1003211.
   PubMed Web of Science ®Google Scholar
• Stohr W, Fidler S, McClure M, et al. Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS One. 2013;8(10):e78287.
   PubMed Web of Science ®Google Scholar
• Williams JP, Hurst J, Stohr W, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife. 2014;3:e03821.
   PubMed Web of Science ®Google Scholar
• Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med. 2012;172(16):1252–1255.
   PubMedGoogle Scholar
• Steingrover R, Pogany K, Fernandez Garcia E, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS (London, England). 2008;22(13):1583–1588.
   PubMed Web of Science ®Google Scholar
• Luzuriaga K, Tabak B, Garber M, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J Infect Dis. 2014;210(10):1529–1538.
   PubMed Web of Science ®Google Scholar
• Persaud D, Palumbo PE, Ziemniak C, et al. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS (London, England). 2012;26(12):1483–1490.
   PubMed Web of Science ®Google Scholar
• Uprety P, Chadwick EG, Rainwater-Lovett K, et al. Cell-associated HIV-1 DNA and RNA decay dynamics during early combination antiretroviral therapy in HIV-1-infected infants. Clinical Infect Dis: Official Pub Infect Dis Soc Am. 2015;61(12):1862–1870.
   PubMed Web of Science ®Google Scholar
• Uprety P, Patel K, Karalius B, et al. Human immunodeficiency virus type 1 DNA decay dynamics with early, long-term virologic control of perinatal infection. Clinical Infect Dis: Official Pub Infect Dis Soc Am. 2017;64(11):1471–1478.
   PubMed Web of Science ®Google Scholar
• Ananworanich J, Puthanakit T, Suntarattiwong P, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS (London, England). 2014;28(7):1015–1020.
   PubMed Web of Science ®Google Scholar
• McManus M, Mick E, Hudson R, et al. Early combination antiretroviral therapy limits exposure to HIV-1 replication and cell-associated HIV-1 DNA levels in infants. PLoS One. 2016;11(4):e0154391.
   PubMed Web of Science ®Google Scholar
• Martinez-Bonet M, Puertas MC, Fortuny C, et al. Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy. Clinical Infect Dis: Official Pub Infect Dis Soc Am. 2015;61(7):1169–1178.
   PubMed Web of Science ®Google Scholar
• Van Zyl GU, Bedison MA, Van Rensburg AJ, et al. Early antiretroviral therapy in South African children reduces HIV-1-infected cells and cell-associated HIV-1 RNA in blood mononuclear cells. J Infect Dis. 2015;212(1):39–43.
   PubMed Web of Science ®Google Scholar
• Bryson YJ, Luzuriaga K, Sullivan JL, et al. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med. 1992;327(17):1246–1247.
   PubMed Web of Science ®Google Scholar
• Rouzioux C, Costagliola D, Burgard M, et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV infection in newborns french collaborative study group. Am J Epidemiol. 1995;142(12):1330–1337.
   PubMed Web of Science ®Google Scholar
• Kuhn L, Abrams EJ, Matheson PB, et al. Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS (London, England). 1997;11(4):429–435.
   PubMed Web of Science ®Google Scholar
• Kalish LA, Pitt J, Lew J, et al. Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first positive culture. Women and Infants Transmission Study (WITS). J Infect Dis. 1997;175(3):712–715.
   PubMed Web of Science ®Google Scholar
• Penazzato M, Revill P, Prendergast AJ, et al. Early infant diagnosis of HIV infection in low-income and middle-income countries: does one size fit all? Lancet Infect Dis. 2014;14(7):650–655.
   PubMed Web of Science ®Google Scholar
• Technau KG, Kuhn L, Coovadia A, et al. Improving early identification of HIV-infected neonates with birth PCR testing in a large urban hospital in Johannesburg, South Africa: successes and challenges. J Int AIDS Soc. 2017;20(1):1–8.
   PubMedGoogle Scholar
• Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9812):221–228.
   PubMed Web of Science ®Google Scholar
• Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (London, England). 2003;17(13):1871–1879.
   PubMed Web of Science ®Google Scholar
• Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010;363(16):1510–1520.
   PubMed Web of Science ®Google Scholar
• Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012;366(25):2380–2389.
   PubMed Web of Science ®Google Scholar
• Hunt GM, Coovadia A, Abrams EJ, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS (London, England). 2011;25(12):1461–1469.
   PubMed Web of Science ®Google Scholar
• Kuhn L, Hunt G, Technau KG, et al. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS (London, England). 2014;28(11):1673–1678.
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet. 2000;39(4):281–293.
   PubMed Web of Science ®Google Scholar
• Cressey TR, Punyawudho B, Le Coeur S, et al. Assessment of nevirapine prophylactic and therapeutic dosing regimens for neonates. J Acquir Immune Defic Syndr. 2017;75(5):554–560.
   PubMed Web of Science ®Google Scholar
• De Waal R, Kroon SM, Holgate SL, et al. Nevirapine concentrations in preterm and low birth weight HIV-exposed infants: implications for dosing recommendations. Pediatr Infect Dis J. 2014;33(12):1231–1233.
   PubMed Web of Science ®Google Scholar
• Capparelli E, Maswabi K, Rossi S, et al. Nevirapine (NVP) concentrations in HIV-infected newborns receiving therapeutic dosing. Paper presented at: 23rd Conference on Retroviruses and Opportunistic Infections. Boston, MA. 2016.
   Google Scholar
• Food and Drug Administration. 2016. Lopinavir/ritonavir (Kaletra) [package insert]. cited 2017 Feb 15. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021251s052_021906s046lbl.pdf
   Google Scholar
• Musoke P, Szubert AJ, Musiime V, et al. Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years. AIDS (London, England). 2015;29(13):1623–1632.
   PubMed Web of Science ®Google Scholar
• Prendergast A, Mphatswe W, Tudor-Williams G, et al. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS (London, England). 2008;22(11):1333–1343.
   PubMed Web of Science ®Google Scholar
• Clarke DF, Acosta EP, Rizk ML, et al. Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr. 2014;67(3):310–315.
   PubMed Web of Science ®Google Scholar
• Rizk ML, Du L, Bennetto-Hood C, et al. Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age. J Clin Pharmacol. 2015;55(7):748–756.
   PubMed Web of Science ®Google Scholar
• Nachman S, Alvero C, Acosta EP, et al. Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. J Pediatric Infect Dis Soc. 2015;4(4):e76–83.
   PubMed Web of Science ®Google Scholar
• Ripamonti D, Tatarelli P, Mangili G, et al. Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates. J Chemother. 2016;28(4):337–340.
   PubMed Web of Science ®Google Scholar
• Ostrowski M, Benko E, Yue FY, et al. Intensifying antiretroviral therapy with raltegravir and maraviroc during early human immunodeficiency virus (HIV) infection does not accelerate HIV reservoir reduction. Open Forum Infect Dis. 2015;2(4):ofv138.
   PubMed Web of Science ®Google Scholar
• IMPAACT Network. P1115 (DAIDS ID 11954): very early intensive treatment of HIV-infected infants to achieve HIV remission: a phase i/ii proof of concept study. [cited 2017 Oct 30]. Available from: http://impaactnetwork.org/studies/P1115.asp
   Google Scholar
• Huang Y, Zhang L, Ledgerwood J, et al. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. mAbs. 2017;9(5):792–800.
   PubMed Web of Science ®Google Scholar
• National Department of Health. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. Pretoria, South Africa: South African National Department of Health; 2015.
   Google Scholar
• Bitnun A, Samson L, Chun TW, et al. Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood. Clinical Infect Dis: Official Pub Infect Dis Soc Am. 2014;59(7):1012–1019.
   PubMed Web of Science ®Google Scholar
• Giacomet V, Trabattoni D, Zanchetta N, et al. No cure of HIV infection in a child despite early treatment and apparent viral clearance. Lancet. 2014;384(9950):1320.
   PubMed Web of Science ®Google Scholar
• Hainaut M, Peltier CA, Gerard M, et al. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1. Eur J Pediatr. 2000;159(10):778–782.
   PubMed Web of Science ®Google Scholar
• Clarke DF, Yildirim I, Cooper ER. Rapid initiation of antiretrovirals in two newly diagnosed HIV-infected infants. Pediatr Infect Dis J. 2017;36(1):61–62.
   PubMed Web of Science ®Google Scholar
• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173–1180.
   PubMed Web of Science ®Google Scholar
• Goetghebuer T, Le Chenadec J, Haelterman E, et al. Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. Clinical Infect Dis: Official Pub Infect Dis Soc Am. 2012;54(6):878–881.
   PubMed Web of Science ®Google Scholar
• Frange P, Faye A, Avettand-Fenoel V, et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. The Lancet HIV. 2016;3(1):e49–54.
   PubMed Web of Science ®Google Scholar
• McMahon JH, Chang J, Tennakoon S, et al. Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy. AIDS (London, England). 2017;31(9):1344–1346.
   PubMed Web of Science ®Google Scholar
• Violari A, Cotton MF, Kuhn L, et al. Viral and host characteristics of a child with perinatal HIV-1 following a prolonged period after ART cessation in the CHER trial. 9th IAS Conference on HIV Science, Paris. 2017 Jul 23–26.
   Google Scholar
• Kuhn L, Technau K, Strehlau R, et al. Treatment of acute HIV infection in neonates. Paper presented at: 24th Conference on Retroviruses and Opportunistic Infections. Seattle, WA. 2017.
   Google Scholar
• Tobin NH, Aldrovandi GM. Are infants unique in their ability to be “functionally cured” of HIV-1? Curr HIV/AIDS Rep. 2014;11(1):1–10.
   PubMed Web of Science ®Google Scholar